These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24318802)

  • 1. De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).
    Fabrizi F; Aghemo A; Moroni G; Passerini P; D'Ambrosio R; Martin P; Messa P
    Dig Dis Sci; 2014 Mar; 59(3):691-5. PubMed ID: 24318802
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC; Chien RN
    Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
    [No Abstract]   [Full Text] [Related]  

  • 3. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
    Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
    [No Abstract]   [Full Text] [Related]  

  • 5. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
    Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
    Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
    [No Abstract]   [Full Text] [Related]  

  • 6. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 8. [Chronic hepatitis C: improved cure rates with new approved medications].
    Grammatikos G; Vermehren J; Zeuzem S
    MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():65-9; quiz 70. PubMed ID: 22916428
    [No Abstract]   [Full Text] [Related]  

  • 9. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
    Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
    Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
    [No Abstract]   [Full Text] [Related]  

  • 10. Long term suppressive therapy with pegylated interferon for chronic hepatitis C associated membranoproliferative glomerulonephritis.
    Cua IH; Kwan V; Henriquez M; Kench J; George J
    Gut; 2006 Oct; 55(10):1521-2. PubMed ID: 16966706
    [No Abstract]   [Full Text] [Related]  

  • 11. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
    Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
    J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
    [No Abstract]   [Full Text] [Related]  

  • 12. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 13. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 14. Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b.
    Ann Intern Med; 2009 Apr; 150(8):I-34. PubMed ID: 19380849
    [No Abstract]   [Full Text] [Related]  

  • 15. [Diabetes mellitus during interferon therapy].
    Tarabini-Castellani P; Apraiz L; Portu J; Agud JM
    Enferm Infecc Microbiol Clin; 2008 Feb; 26(2):120-1. PubMed ID: 18341927
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversible sudden hearing loss in a chronic hepatitis C patient who achieved a sustained response to antiviral re-treatment.
    Zampino R; Costa G; Barillari M; Adinolfi LE; Marrone A
    Infez Med; 2012 Jun; 20(2):117-9. PubMed ID: 22767311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy for chronic viral hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622
    [No Abstract]   [Full Text] [Related]  

  • 18. [Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
    Wikman Jorgensen PE; Jover Díaz FM; Cuadrado Pastor JM
    Gastroenterol Hepatol; 2007 Apr; 30(4):253. PubMed ID: 17408558
    [No Abstract]   [Full Text] [Related]  

  • 19. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
    Papastergiou V; Skorda L; Lisgos P; Karatapanis S
    Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of chronic hepatitis C].
    Schaffstein S; Rampini SK; Müllhaupt B
    Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.